China’s Biopharma Opportunity: From Pipeline Assets to Development Platforms
China has become one of the world’s most important biopharma innovation hubs, reshaping how companies source assets and pursue global growth. This whitepaper explores the next phase of cross-border collaboration and revealing what deal structures tell us about buyer confidence.
